ALT

1.3305.67%
CA

Christophe Arbet-Engels

Chief Medical Officer

Dr. Christophe Arbet-Engels, MD, PhD, MBA, is Chief Medical Officer of Altimmune, Inc. from October 1, 2025. Dr. Arbet-Engels was Chief Medical Officer at X4 Pharmaceuticals, Inc. from August 2023 until September 16, 2025. He serves as Clinical Advisory Board Member at ViaCyte, Inc. since February 2022. Dr. Arbet-Engels served as Chief Medical Officer at Neurogastrx, Inc. since August 2021. Dr. Arbet-Engels served as Chief Medical Officer at Millendo Therapeutics, Inc. since February 2020 until 2021. Dr. Arbet-Engels had been Chief Medical Officer of Poxel SA since March 07, 2017 and served as its Executive Vice President of Phase-III Clinical Development & Medical Affairs until November 2019. Dr. Arbet-Eng is a seasoned pharmaceutical and biotech executive. Dr. Arbet-Eng has extensive experience spanning the spectrum of drug research and development to commercialization, patient access and life-cycle management. In particular, Dr. Arbet-Engels has led development of large-scale registration studies for diabetes drugs and studies for cardiovascular disease and outcome. Dr. Arbet-Engels has experience in life sciences, academia and industry. He has served in senior leadership roles for programs with a focus in diabetes-metabolism and led programs, in complex global and local settings, ranging from diabetes, cardiovascular-metabolism, neurology, orphan diseases to oncology. Dr. Arbet-Engels’ leadership at several large pharmaceutical companies encompasses clinical development and registration, launch and lifecycle management for several innovative drugs for the treatment of diabetes, metabolism and cardiovascular diseases, including Lantus® (insulin glargine) and Jardiance® (empagliflozin). Most recently, he was Vice President of Worldwide Medical, Collaborative Medical Sciences at Biogen, driving strategy and execution of Phase 3b/4 life cycle management activities across several therapeutic areas ranging from neurology, hematology to rare diseases. In this position, Dr. Arbet-Engels built, developed and led global medical research, clinical operations, biostatistics/analytics, communication and expanded access program teams to advance the medical sciences in areas of interest to Biogen. Prior to Biogen, Dr. Arbet-Engels worked in senior leadership positions in clinical development and medical affairs, in global or local roles, at pharmaceutical and biotech companies, including Boehringer Ingelheim, Roche, Merck, Aventis (now Sanofi) and Ligand Pharmaceuticals. In addition, Dr. Arbet-Engels served as a Medical Advisor to MedNest, provided expertise to the Gerson Lehrman Group and worked as French Foreign Trade Advisor for the French Government to advise and support French or other startup companies develop their business in the U.S. Dr. Arbet-Engels has also served in educational roles at The Salk Institute for Biological Studies, University of Paris VI and the Assistance Publique, Hospitals of Paris and serves as a Member of the Board of Tutors in Biochemical Sciences at Harvard University. Dr. Arbet-Engels has a medical degree from University of Paris Sud, a PhD in endocrinology/diabetes and metabolism from Paris Descartes University and a master’s degree in business administration from Rutgers University.

Positions